Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell–Depleted Stem Cell Transplantation
Open Access
- 18 June 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (9) , 618.e1-618.e10
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Immune reconstitution after combined haploidentical and umbilical cord blood transplantLeukemia & Lymphoma, 2012
- Adenoviremia Has Limited Clinical Impact in the Majority of Patients Following Alemtuzumab-Based Allogeneic Stem Cell Transplantation in AdultsClinical Infectious Diseases, 2012
- Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsBlood, 2011
- T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseLeukemia & Lymphoma, 2010
- Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionBlood, 2010
- Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrenceLeukemia & Lymphoma, 2009
- Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term OutcomesTransplantation and Cellular Therapy, 2009
- Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioningBone Marrow Transplantation, 2006
- Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic SyndromeJournal of Clinical Oncology, 2005
- Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumabTransplantation and Cellular Therapy, 2004